Calidi Biotherapeutics (CLDI) Non Operating Investment Income (2022 - 2023)
Calidi Biotherapeutics' quarterly Non Operating Investment Income came in at $12848.0 in Q2 2023, down 54.09% quarter-over-quarter from $27986.0 in Q1 2023.
Calidi Biotherapeutics has reported Non Operating Investment Income for 2 years, with the latest figure at $12848.0 in Q2 2023.
- For the quarter ending Q2 2023, Non Operating Investment Income changed N/A year-over-year to $12848.0; the trailing twelve-month figure through Jun 2023 stood at $40834.0 (changed N/A YoY), and the FY2025 full-year result was $244000.0, changed N/A from the prior year.
- Non Operating Investment Income for Q2 2023 stood at $12848.0, down from $27986.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $27986.0 in Q1 2023, with the low at $2266.0 in Q1 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 230,000.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | - |
| 10 | Calidi Biotherapeutics | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 12,848.00 |
| Jun 30, 2023 | 12,848.00 |
| Mar 31, 2023 | 27,986.00 |
| Mar 31, 2023 | 27,986.00 |
| Mar 31, 2022 | 2,266.00 |
| Mar 31, 2022 | 2,266.00 |